Management of Community-Acquired Pneumonia: Defining the Role of Azithromycin
Abstract
Community-acquired pneumonia (CAP) is a common cause of morbidity and mortality and is associated with the consumption of considerable health resources worldwide. Initial treatment of patients with CAP is often empirical. Growing concern about the increasing prevalence of atypical organisms is reflected in North American guidelines, which place considerable emphasis on the use of the macrolides. Azithromycin, the prototype azalide, is a macrolide derivative with a broad antimicrobial spectrum including enhanced activity against Haemophilus influenzae relative to erythromycin. Its distinctive pharmacokinetic profile is characterised by extensive and prolonged tissue distribution accompanied by low serum drug concentrations. An estimated tissue half-life of between 2 and 3 days enables the drug to be administered as a once daily, abbreviated regimen for the treatment of patients with CAP. This provides the drug with an advantage over other macrolides including erythromycin and clarithromycin, which require a longer treatment duration. However, the potential for prolonged subinhibitory tissue concentrations of azithromycin to promote the development of resistant microorganisms requires further evaluation. Clinical trials have demonstrated the efficacy of 3- to 5-day regimens of oral azithromycin (total dose 1.5g) in patients with CAP. These regimens were generally as effective as longer treatment durations with other commonly used antimicrobials including other macrolides and amoxicillin/clavulanic acid. Importantly, azithromycin is well tolerated and is associated with a lower incidence of gastrointestinal adverse events than erythromycin. Azithromycin is also associated with fewer pharmacokinetic drug interactions than erythromycin or clarithromycin. According to US prescribing information, orally administered azithromycin is not recommended for use (presumably as monotherapy) in patients with moderate to severe pneumonia, bacteraemia or significant underlying health problems, or in elderly or debilitated patients. A recently developed intravenous formulation of azithromycin may be of value in some of these patients but this requires confirmation. Conclusion: Oral azithromycin is an attractive antimicrobial option in patients with mild CAP and has a role in both empirical therapy and pathogen-directed treatment against atypical organisms. However, its usefulness, as for other macrolides, may be limited in regions with a high prevalence of macrolide-resistant pneumococci. Particular benefits over erythromycin and some other macrolides include enhanced activity against Gram-negative pathogens, an improved tolerability profile, a once daily abbreviated treatment regimen (which may result in improved patient compliance) and few pharmacokinetic drug interactions. The development of an intravenous preparation may expand the use of azithromycin in patients with CAP requiring hospitalisation.Download Info
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Bibliographic Info
Article provided by Wolters Kluwer Health | Adis in its journal Disease Management & Health Outcomes.
Volume (Year): 5 (1999)
Issue (Month): 1 ()
Pages: 41-54
Download reference. The following formats are available: HTML
(with abstract),
plain text
(with abstract),
BibTeX,
RIS (EndNote, RefMan, ProCite),
ReDIF
Handle: RePEc:wkh:dmhout:v:5:y:1999:i:1:p:41-54
Contact details of provider:
Web page: http://diseasemanagement.adisonline.com/
For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).
Related research
Keywords: Reviews-on-treatment; Azithromycin; Pneumonia; Azithromycin; Children; Adults; Antimicrobial-resistance; Pharmacoeconomics; Cost-effectiveness; Clinical-pharmacokinetics; Antibacterials;Find related papers by JEL classification:
- C - Mathematical and Quantitative Methods
- D - Microeconomics
- I - Health, Education, and Welfare
- Z - Other Special Topics
- I1 - Health, Education, and Welfare - - Health
- I19 - Health, Education, and Welfare - - Health - - - Other
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
References
No references listed on IDEASYou can help add them by filling out this form.
Citations
Lists
This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.Statistics
Access and download statisticsCorrections
When requesting a correction, please mention this item's handle: RePEc:wkh:dmhout:v:5:y:1999:i:1:p:41-54For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.